Zassi Medical Evolutions Inc.
This article was originally published in Start Up
Hoping to eliminate the stigma and inconvenience of ostomies, Zassi Medical Evolutions Inc. has developed a bag-free system for managing the waste that is redirected through a stoma in the abdominal wall. Zassi's Continent Ostomy Port system is designed to free patients from external collection devices taped to their stomachs. The company has signed a licensing and distribution deal with ostomy market leader Bristol-Myers Squibb's ConvaTec division.
You may also be interested in...
The latest accelerated approval withdrawals in the US are milestones for accountability in the program – most notably with the withdrawal of an antimicrobial with confirmatory studies more than a decade overdue.
Based on promising Phase II data, two companies in South Korea are moving ahead with late-stage development in the gout space, with JW Pharmaceutical getting approvals to begin a multinational Phase III trial for epaminurad, while LG Chem has recently submitted an application for a Phase III program with its contender tigulixostat.
Final guidance targets the ‘multiplicity problem.’ At about half the length of the 2017 draft, the final removes some sections, truncates other and drops several examples.